← Eichor
Study identifier: NCT05180097 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Condition: Hodgkin Lymphoma  ·  Sponsor: Canadian Cancer Trials Group

PhasePhase 2
Planned participants84
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Annette Hay  ·  613-533-6430  ·  ahay@ctg.queensu.ca

Lois Shepherd  ·  613-533-6430  ·  lshepherd@ctg.queensu.ca

Always discuss trial participation with your own doctor first.

Locations (18)

Concord Repatriation General HospitalConcord, New South Wales, AustraliaRecruiting
Shoalhaven Cancer Care CentreNowra, New South Wales, AustraliaRecruiting
Wollongong HospitalWollongong, New South Wales, AustraliaRecruiting
Royal Adelaide HospitalAdelaide, South Australia, AustraliaRecruiting
Austin HospitalHeidelberg, Victoria, AustraliaRecruiting
Sir Charles Gairdner HospitalPerth, Western Australia, AustraliaRecruiting
Arthur J.E. Child Comprehensive Cancer CentreCalgary, Alberta, CanadaRecruiting
BCCA - VancouverVancouver, British Columbia, CanadaRecruiting
Dr. H. Bliss Murphy Cancer CentreSt. John's, Newfoundland and Labrador, CanadaRecruiting
QEII Health Sciences CentreHalifax, Nova Scotia, CanadaRecruiting
Juravinski Cancer Centre at Hamilton Health SciencesHamilton, Ontario, CanadaRecruiting
London Health Sciences Centre Research Inc.London, Ontario, CanadaRecruiting

+ 6 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05180097